ATP13A2 and Parkinson disease: Another study of 35 untreated and 12 treated patients with the sporadic form of PD (Hoehn and Yahr score 1–2) proposed a method for analyzing the expression of micro-RNA levels of ATP13A2, PARK7, and ZNF746 in the peripheral blood, which can be suggested also as potential biomarkers of the preclinical stage of PD [89].